title: Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.
abstract: Chemotherapy-associated interstitial lung disease (ILD) is often fatal, and the chemotherapeutic regimen generally cannot be resumed. ILD associated with the mammalian target of rapamycin (mTOR) inhibitor everolimus has many features distinct from chemotherapy-associated ILD. We present the case of a 58-year-old woman with an advanced pancreatic neuroendocrine tumor with liver metastases, in whom everolimus treatment was maintained and resulted in a partial response despite two occurrences of everolimus-induced ILD during a 31-month treatment period until disease progression. Physicians treating with everolimus should monitor patients closely for ILD and should apply appropriate management strategies to optimize the possibility of maintaining everolimus therapy.
authors.affiliation: Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakayama
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ikeda
authors.forename: Motohiro
authors.initials: M
authors.lastname: Kojima
authors.forename: Koichi
authors.initials: K
authors.lastname: Goto
authors.forename: Miyuki
authors.initials: M
authors.lastname: Hara
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okuyama
authors.forename: Hideaki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Izumi
authors.initials: I
authors.lastname: Ohno
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shimizu
authors.forename: Shuichi
authors.initials: S
authors.lastname: Mitsunaga
authors.forename: Takuji
authors.initials: T
authors.lastname: Okusaka
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D000068338:Everolimus; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000378:metabolism; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; C060192:MUC1 protein, human; D018396:Mucin-1; D002097:C-Reactive Protein; D000068338:Everolimus; D020123:Sirolimus